AUSTRALIAN listed bio-pharmaceutical company Zelda Therapeutics has announced it placed 85,714,286 shares at AU$0.07 per share raising $6m and was oversubscribed with strong support from Australasian institutional investors.
Zelda has secured exclusive, global access to what it calls "an extensive set of human data related to medicinal cannabis based formulations and treatment protocols" over several years.
The company says it is conducting human clinical trials initially in sleep disorder (insomnia) and eczema indications as well as building a pre-clinical cancer research portfolio.
CLICK HERE for the ASX release.
AusCann has a preferential supplier agreement with Zelda for cannabis product research trials.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Apr 17